#USA #Orlando #OncoPrecision #ONC001 #monocytic leukemia

OncoPrecision Presents ONC001 at the ASH Annual Meeting

OncoPrecision Corporation, a forward-thinking biotechnology firm focused on developing innovative cancer therapies, has announced that its lead drug candidate, ONC001, will be showcased through an oral presentation at the upcoming 67th Annual Meeting and Exposition of the American Society of Hematology (ASH). This prestigious event is set to occur from December 6 to 9, 2025, in Orlando, Florida.

About ONC001

ONC001 is a pioneering antibody-drug conjugate (ADC) that is specifically designed to target CD64, a myeloid-restricted receptor significantly expressed in monocytic leukemia and acute myeloid leukemia types M4 and M5, particularly in highly resistant subpopulations. Developed utilizing OncoPrecision's proprietary discovery engine, this drug candidate integrates large-scale patient-derived biology along with advanced AI-powered high-throughput screening to pinpoint the most relevant cellular vulnerabilities.

This unique methodology enabled the identification of a lead antibody with a high affinity for an undervalued target, alongside the optimal payload and linker chemistry of the ADC to minimize off-target toxicity and preserve healthy hematopoiesis. As ONC001 progresses toward Investigational New Drug (IND) studies, it signifies a differentiated approach to overcoming resistance often induced by monocytic therapy.

Presentation Highlights

Co-founder and Chief Scientific Officer, Dr. Gastón Soria, is slated to present preclinical data that underscoring three significant areas:

1. Selective Engagement: Demonstrating how ONC001 selectively attracts cells derived from patients with monocytic leukemia and acute myeloid leukemia.
2. Robust Activity: Showcasing its compelling effectiveness against samples resistant to current standard therapies.
3. In Vivo Efficacy: Sharing strong in vivo data from both heterotopic and orthotopic models showing the potential success of ONC001.

Dr. Tarek Zaki, co-founder and CEO of OncoPrecision, expressed his enthusiasm about the upcoming presentation, emphasizing that being selected for an oral session at ASH highlights the fundamental strength of this novel therapeutic approach. “ONC001 is specifically designed to target the resistance mechanisms that drive certain aggressive hematologic cancers, thus providing a new pathway to overcome common therapeutic failures. We look forward to sharing our findings with the global hematology community and engaging in discussions with potential strategic and development partners.”

Dr. Soria adds, “ONC001 is a direct result of our platform’s capability to integrate patient-derived biological insights with rational target selection and payload compatibility. Although CD64 has been recognized for years as a biomarker for monocytic leukemia, no approved or clinical-phase asset has successfully utilized it as a therapeutic target. Our platform has revealed that an ADC modality is the optimal pathway to achieve this goal.”

Presentation Details

• - Title: ONC001: A Pioneering First-In-Class ADC Targeting CD64 for Monocytic Leukemia Developed Through Patient-Guided Target and Payload Selection.
• - Presenter: Dr. Gastón Soria, Co-Founder and Chief Scientific Officer of OncoPrecision.
• - Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Neoplasms: New Strategies to Overcome Therapeutic Resistance in AML.
• - Date: Saturday, December 6, 2025.
• - Session Time: 4:00 PM to 5:30 PM.
• - Presentation Slot: 5:15 PM to 5:30 PM.
• - Location: OCCC, Valencia Room W415D.

About OncoPrecision

OncoPrecision is an advanced oncology company that leverages large-scale patient-derived biology and AI-optimized discovery platforms to develop precision medicines with a higher likelihood of clinical success. The firm integrates translational biology, machine learning, and modular ADC/BsAb engineering to create a portfolio of first-rate interventions in hematological neoplasms and solid tumors. OncoPrecision is actively exploring collaborations and strategic alliances to expedite the development and commercialization of its programs.

Forward-Looking Statements

This press release contains forward-looking statements about the development, safety, and therapeutic potential of ONC001 and other product candidates. Actual results may differ significantly from those expressed or implied due to inherent risks and uncertainties in drug development. OncoPrecision does not assume any obligation to update or revise these statements.